Project Grant R01AI184531
Award Date
3/25/25
Completion Date
2/28/30
Dollars Obligated
$751K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Baltimore, MD 21201, USA
Similar Awards
This Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $170,000.00 to Prokaryotics Incorporated to support research and development of a novel antifungal agent that inhibits the glycosylphosphatidylinositol (GPI) biosynthesis pathway in fungal pathogens.
The key goals of this 2-year project are to: 1) Perform cryo-EM structural studies to elucidate the molecular interactions between the lead...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $418,682 to Cornell University to conduct research on the evolutionary history and symbiotic associations of opportunistic fungal pathogens that cause mucormycosis infections in humans. The key objectives are to elucidate the population-level processes governing the relationship between the Mucoromycotina fungi and...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $433,577 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Tulane University to develop in vitro precision cut lung slice (PCLS) models of Pneumocystis fungal infection. The goal is to refine this model and test different culturing conditions to optimize fungal attachment, survival, and growth. The researchers will also investigate whether this PCLS model can be used for...
The Project Grant award of $344,534, awarded by the National Institute of Allergy and Infectious Diseases (CFDA Program 93.855 Allergy and Infectious Diseases Research), aims to establish ex vivo growth systems for the fungal genus Pneumocystis, which causes a life-threatening pneumonia in immunodeficient individuals.
The key objectives are to: 1) Use metabolomics and flux balance analysis to identify critical nutrients for culturing the rat surrogate model Pneumocystis carinii in a cell-free...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $1,421,153 Project Grant (CFDA 93.855 - Allergy and Infectious Diseases Research) to The Regents of the University of Colorado to develop novel antifungal agents against coccidioidomycosis, a serious fungal infection endemic to the Southwestern United States. The overarching goal of this 5-year collaborative project is to optimize the antifungal activity of synthetic analogs as a potential lead for treating Valley...
This federal Project Grant award of $1,042,754 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 Allergy and Infectious Diseases Research program) supports research to define the mechanisms by which the calcineurin enzyme regulates antifungal response and resistance in the Aspergillus fumigatus fungus. The project aims to identify key calcineurin effectors that govern cell wall and membrane integrity, and elucidate calcineurin's transcriptional and post-translational...
This $435,577 federal Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) aims to elucidate the molecular mechanisms by which the septin cytoskeleton in the human pathogen Aspergillus fumigatus mediates the fungistatic response to the antifungal drug caspofungin. The 5-year project, conducted by Virginia Polytechnic Institute & State University, will 1) determine the role of the septin cytoskeleton in...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $895,538 to Hackensack University Medical Center to develop shorter and more effective oral regimens for treating Mycobacterium abscessus pulmonary disease (MAB-PD). The key objectives are to:
Propose optimized drug regimens with the greatest potential to rapidly reduce bacterial burden and achieve sterilization in a mouse model of MAB...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $249,749 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of Iowa. The objective of this 2-year project is to develop a new approach to analyzing the transcriptional control of virulence in the human fungal pathogen Aspergillus fumigatus. The project will involve preparing fusion proteins of 8 transcription factors known to be required for A. fumigatus virulence,...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $368,125 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The University of Texas Health Science Center at San Antonio (UTHSCSA). The grant supports a 2-year research project to investigate the role of translational mechanisms in controlling conidial germination, a critical virulence process, in the human fungal pathogen Aspergillus fumigatus. The project aims to determine the...